Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593098 | 0.88 | RORC (0.41) | RORCMEN1KMT2AHSD11B1LMNA | |
| SCHEMBL927334 | 0.87 | RORC (0.49) | RORCMEN1KMT2AHSD11B1 | |
| SCHEMBL926085 | 0.84 | LMNA (0.50) | MEN1KMT2AHSD11B1LMNAALDH1A1 | |
| SCHEMBL3591921 | 0.84 | LMNA (0.50) | MEN1KMT2AHSD11B1LMNAALDH1A1 | |
| SCHEMBL927296 | 0.75 | ESR1 (0.54) | RORCMEN1KMT2AHSD11B1LMNA | |
| SCHEMBL926444 | 0.74 | HSD11B1 (0.50) | HSD11B1LMNAALDH1A1 | |
| SCHEMBL3588564 | 0.72 | LMNA (0.47) | MEN1KMT2AHSD11B1LMNAALDH1A1 | |
| SCHEMBL926520 | 0.72 | MEN1 (0.43) | MEN1KMT2AHSD11B1LMNAALDH1A1 | |
| SCHEMBL926157 | 0.70 | RORC (0.51) | RORCMEN1KMT2AALDH1A1GAA | |
| SCHEMBL15280427 | 0.70 | LMNA (0.67) | LMNAALDH1A1POLBAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781481-B2 | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | claimed |
| CN-101326164-A | Inhibitors of CCR9 activity | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | claimed |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | claimed |
| EP-1968939-A2 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | claimed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-7781481-B2 | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| CN-101326164-A | Inhibitors of CCR9 activity | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1968939-A2 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | RORC 191/4885MEN1 4071/4885KMT2A 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.